(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 113.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Cytokinetics's revenue in 2026 is $87,211,000.On average, 20 Wall Street analysts forecast CYTK's revenue for 2026 to be $15,900,554,016, with the lowest CYTK revenue forecast at $6,482,242,006, and the highest CYTK revenue forecast at $26,191,593,090. On average, 17 Wall Street analysts forecast CYTK's revenue for 2027 to be $45,733,196,692, with the lowest CYTK revenue forecast at $33,395,442,707, and the highest CYTK revenue forecast at $62,812,384,624.
In 2028, CYTK is forecast to generate $111,888,304,476 in revenue, with the lowest revenue forecast at $72,405,290,954 and the highest revenue forecast at $182,419,274,068.